Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer

Abstract Background Loss of HER2 “positivity” can occur in patients with residual disease after neoadjuvant treatment, but the incidence of HER2‐positivity loss after neoadjuvant dual HER2‐targeted treatment plus chemotherapy, the current standard‐of‐care for most early stage HER2‐positive breast ca...

Full description

Bibliographic Details
Main Authors: Alexis LeVee, Kellie Spector, Brigid Larkin, Felipe Dezem, Jasmine Plummer, Farnaz Dadmanesh, Sujata Patil, Heather L. McArthur
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
breast cancer
discordance
dual
HER2
neoadjuvant therapy
Online Access:https://doi.org/10.1002/cam4.5817

Internet

https://doi.org/10.1002/cam4.5817

Similar Items